Onkure Therapeutics Inc Revenue Growth Rates (OKUR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Onkure Therapeutics Inc   (NASDAQ: OKUR)
 

OKUR's Revenue Growth by Quarter and Year

Onkure Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OKUR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.00
1st Quarter March 0.46
FY 0.46





OKUR Revenue second quarter 2026 Y/Y Growth Comment
Onkure Therapeutics Inc in the second quarter 2026 recorded of $ 0.00 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 150 other companies have achieved higher Revenue growth. While Onkure Therapeutics Inc ' s Revenue meltdown of -100% ranks overall at the positon no. 3285 in the second quarter 2026.


OKUR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -63.74 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March -57.41 % - - -
FY   - 100.58 % - -

Financial Statements
Onkure Therapeutics Inc 's second quarter 2026 Revenue $ 0.00 millions OKUR's Income Statement
Onkure Therapeutics Inc 's second quarter 2025 Revenue $ 0.93 millions Quarterly OKUR's Income Statement


OKUR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -22.5 % - -
3rd Quarter September - -13.98 % - -
2nd Quarter June - -13.89 % - -
1st Quarter March -25.81 % -36.84 % - -
FY (Year on Year)   - 100.58 % - -


Back to OKUR Growth rate Comparisons >> Back to OKUR Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #151
Healthcare Sector #449
Overall #3285

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #151
Healthcare Sector #449
Overall #3285
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Onkure Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OKUR's II. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Onkure Therapeutics Inc come out even worse considering the 0.46 millions a quarter before.

Within Major Pharmaceutical Preparations industry Onkure Therapeutics Inc achieved highest sequential Revenue growth. While Onkure Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OKUR's II. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Onkure Therapeutics Inc come out even worse considering the 0.46 millions a quarter before.

Within Major Pharmaceutical Preparations industry Onkure Therapeutics Inc achieved highest sequential Revenue growth. While Onkure Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is .


Onkure Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 2.82 $ 3.43 $ 4.52 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - -17.97 % -24.12 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 3285 # 3279 # 2747 # 0 # 0


Cumulative Revenue growth Comment
In the Jun 30 2026 period, Onkure Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Onkure Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 151
Sector # 449
S&P 500 # 3285
Cumulative Revenue growth Comment
In the Jun 30 2026 period, Onkure Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Onkure Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 151
Sector # 449
S&P 500 # 3285




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OKUR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Onkure Therapeutics Inc Revenue Growth Rates (OKUR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Onkure Therapeutics Inc (CIK 1637715).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-332773
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Onkure Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.